Anti-inflammatory Drugs Market By Drug Class (Anti-inflammatory Biologics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids) By Application (Autoimmune Inflammatory Diseases, Respiratory Diseases, Others) – Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Key Highlights of the Report

The global market for anti-inflammatory drugs is divided into drug class, application, method of administration, distribution channel, and region. Anti-inflammatory drugs are the most commonly used in autoimmune inflammatory illnesses, with oral and injectable being the two basic routes of administration. Furthermore, corticosteroids account for a significant share of the anti-inflammatory medications sector, the online pharmacy industry is expanding in popularity due to the convenience and accessibility it provides to patients in need of anti-inflammatory drugs, and North America has emerged as the largest market.

The frequency of inflammation-related disorders, as well as prospective pipeline candidates, is driving the worldwide anti-inflammatory medications market. However, the market confronts considerable obstacles, including the increased popularity of NSAID side effects, severe regulatory requirements, and generic competition.

Nonetheless, the global anti-inflammatory drugs market has considerable development prospects, including Biotechnology Advances and the release of novel anti-inflammatory medications. Furthermore, while the Asia-Pacific region is expected to see the most growth in the coming years, North America now has the greatest market for anti-inflammatory drugs.

Market Overview

The global anti-inflammatory drugs market has grown steadily in recent years and is predicted to increase at a 9.80% CAGR between 2023 and 2030. In 2022, the market was valued at USD 100.9 billion, and it is predicted to grow to USD 194.1 billion by 2030.

What Are the Primary Forces Driving the Global Anti-Inflammatory Drugs Market?

The worldwide anti-inflammatory pharmaceuticals market is being pushed by numerous factors, including the increasing frequency of inflammatory diseases and prospective pipeline candidates.

What Are the Global Anti-Inflammatory Drugs Market’s Major Challenges?

The global anti-inflammatory drugs market also faces several challenges, including patent expiration and the emergence of alternative medicines.

What Are the Opportunities for Growth in the Global Anti-Inflammatory Drugs Market?

The worldwide anti-inflammatory pharmaceuticals market provides considerable potential opportunities, including Biotechnology Advances and the introduction of novel anti-inflammatory medications.

Executive Summary

Overview of the Global Anti-Inflammatory Drugs Market

The anti-inflammatory drugs market is the pharmaceutical industry segment that focuses on the development, production, and sale of drugs used to reduce inflammation in the body. Inflammation is the immune system’s natural response to damage or infection, but persistent inflammation can lead to a variety of health problems such as arthritis, asthma, and inflammatory bowel disease. Anti-inflammatory medications are intended to lower inflammation and alleviate symptoms associated with certain illnesses. The anti-inflammatory medicine industry, which includes both prescription and over-the-counter treatments, is being pushed by reasons such as the increased prevalence of chronic inflammatory illnesses, the growing geriatric population, and rising demand for biologic drugs.

Market Definition

Anti-inflammatory drugs are used to treat acute & chronic disorders having an inflammatory aetiology. Therapeutic delivery of anti-inflammatory medications to the site of action while avoiding unwanted side effects. Anti-inflammatory drugs help to enhance the quality of life and management of a variety of rheumatic illnesses, including arthritis. Anti-inflammatory medications, particularly non-steroidal versions, play an important role in medical practise.

Market Insights

• Anti-inflammatory drugs demand was estimated at USD 100.9 billion in 2022 and is predicted to reach USD 1194.1 billion in 2030, expanding at a CAGR of 9.80% between 2023 and 2030.
• Nonsteroidal anti-inflammatory drugs (NSAIDs) led the market in 2022, accounting for 68% of the total.
• The autoimmune inflammatory diseases category is predicted to develop at the fastest CAGR of 9.24%.
• In 2022, the oral segment led the market with a market share of roughly 56%.
• With a market share of roughly 54% in 2022, the retail pharmacies segment dominated the industry.
• With a market share of roughly 39.88%, North America emerged as the largest market for worldwide anti-inflammatory drugs.
• Asia Pacific is predicted to be the largest market throughout the forecast period.
• The prevalence of inflammation-related illnesses and potential pipeline candidates is rising are the major drivers of the market.
• At the same time, Side effects of NSAIDs, stringent regulatory requirements, and generic competition are the main restraints.
• Biotechnology The primary an opportunity in the industry include advances and novel anti-inflammatory medications that are being introduced..

Segmentation by Drug Class

• Nonsteroidal anti-inflammatory drugs (NSAIDs) led the market in 2022, accounting for 68% of the total.
• Corticosteroids account for a sizable portion of the anti-inflammatory drugs industry.
• Anti-inflammatory biologicsis another segment but contributes very little to the global anti-inflammatory drugs market compared to the Nonsteroidal anti-inflammatory drugs (NSAIDs) and Corticosteroids segments.

Segmentation by Application

• The autoimmune inflammatory diseases category is predicted to develop at the fastest CAGR of 9.24%.
• The respiratory diseases segment contributes the rest to the demand for anti-inflammatory drugs.

Segmentation by Route Of Administration

• In 2022, the oral segment led the market with a market share of roughly 56%.
• In the anti-inflammatory drugs market, the injection sector has the highest CAGR.
• The market for anti-inflammatory drugs is expanding quickly in the inhalation category as respiratory disorders are becoming more common.

Segmentation by Distribution Channel

• With a market share of roughly 54% in 2022, the retail pharmacies segment dominated the industry.
• Anti-inflammatory drugs are in great demand in the hospital pharmacy sector in 2022.
• The online pharmacy industry is growing in popularity due to the ease and accessibility it provides to patients in need of anti-inflammatory drugs.

Segmentation by Region

• With a market share of roughly 39.88%, North America emerged as the largest market for worldwide anti-inflammatory drugs.
• Asia Pacific is predicted to be the largest market throughout the forecast period.
• The rest of the World, including Latin America, The Middle East, and Africa, contributes the remainder to the demand for anti-inflammatory drugss.

The increasing demand for anti-inflammatory drugss can be attributed to the prevalence of inflammation-related illnesses and potential pipeline candidates are rising. However, the market is restrained by Side effects of NSAIDs, stringent regulatory requirements, and generic competition.

In terms of revenue, North America led the entire market in 2021, followed by Europe. Some of the primary reasons driving the industry’s growth are the existence of a large number of manufacturers and strategic initiatives implemented by market participants. Furthermore, the rising prevalence of chronic pain and arthritis is expected to drive growth during the forecast period.

During the projection period, Asia-Pacific is expected to be the fastest-growing region. The region’s growth is ascribed to causes such as an ageing population, an increase in the prevalence of chronic pain, migraines, and headaches, as well as an increase in product approvals and launches in the region.

Overall, the rising prevalence of inflammation-related disorders is driving up demand for anti-inflammatory medications, and the number of possible pipeline candidates is growing.

While the market for anti-inflammatory pharmaceuticals is expanding, it is being challenged by patent expiration and the emergence of alternative therapies.

Potential Candidates for the Pipeline

Increasing research efforts in biologics development for the treatment of autoimmune inflammatory illnesses have resulted in prospective pipeline medications. The benefits of monoclonal antibodies’ anti-inflammatory characteristics have turned the emphasis of pharmaceutical behemoths to this field. Anti-tumor necrosis factor (TF) inhibitors, interleukins, and other agents are being developed by the firms to treat a wide range of inflammatory illnesses. For example, UCB S.A. published excellent results from a phase 3 clinical research of Bimekizumab for the treatment of psoriasis in December 2019. Aside from that, the anti-inflammatory medicines market is expected to be driven by research & development of NSAIDs and corticosteroids for treating atopic dermatitis, plaque psoriasis, acute pain, and others over the forecast period.

Inflammatory diseases are becoming more prevalent.

One of the major factors driving the growth of the anti-inflammatory therapies market is the increasing prevalence of inflammatory illnesses such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, ulcerative colitis, and others. The Centres for Disease Control and Prevention estimates that 78 million adults in the United States will have doctor-diagnosed arthritis by 2040.  During the projected period, this is expected to fuel the market. Furthermore, the increasing use of corticosteroids for the treatment of asthma and chronic obstructive pulmonary disease (COPD), as well as the rising prevalence of atopic dermatitis, are likely to drive market growth.

NSAID Side Effects

Non-Steroid Adverse Reactions Anti-inflammatory medications (NSAIDs) are likely to limit market growth due to side effects such as stomach ulcers, allergic reactions, disorientation, stomach pain, and others. Because they are effective anti-inflammatory medicines, NSAIDs are among the most often given medications. However, NSAID-related gastrointestinal problems have the potential to place a strain on the healthcare system. The most prevalent reason for hospitalisation is gastrointestinal bleeding. Gl problems caused by NSAIDs have become the most common adverse effect in the United States. This is projected to reduce market revenue in the next years.

Extensive Regulatory Requirements

The anti-inflammatory drug market is governed by severe regulatory standards, which can limit market expansion and have an impact on drug development. Before authorising new pharmaceuticals, regulatory bodies such as the FDA and EMA demand comprehensive clinical trials and safety data, which can be time-consuming and costly. The regulatory licencing procedure can also be complicated and difficult to navigate, especially for small businesses with limited resources. This may impede small companies’ capacity to enter the market and compete with larger, more established players.

Furthermore, regulatory agencies are increasingly focused on anti-inflammatory drug safety and efficacy, which can raise the cost and time required to bring new treatments to market. To address these issues, pharmaceutical companies are investing in innovative technology and drug development methodologies that can assist streamline the regulatory approval process and cut costs. These initiatives, however, may take time to bear fruit, and the regulatory landscape is likely to remain difficult for the foreseeable future.

Generic Competition

The market for anti-inflammatory medications is highly competitive, with many generic drugs accessible at cheaper prices than branded drugs. This may impede market expansion and have an influence on branded drug sales. Generic medications are often less expensive than branded drugs since they do not necessitate the same amount of R&D expenditure and can be made and sold by various producers. As a result, in order to save money, many patients and healthcare professionals prefer generic medications over branded drugs. This can reduce the market share and profitability of branded pharmaceuticals. To solve this issue, pharmaceutical companies are investing in innovative medication delivery technologies and formulations that have higher efficacy and fewer adverse effects than present treatments. However, these efforts can be costly and time-consuming, and they may not be sufficient to overcome generic competition.

Innovative Anti-Inflammatory Drugs Are Being Introduced

The launch of novel anti-inflammatory drugs is a prominent trend that is positively impacting the growth of the global anti-inflammatory therapeutics market. Cytokines are proteins produced by immune cells. These protein molecules allow cells to communicate with one another and are required for cell proliferation and differentiation, as well as immune system modulation. Small molecules that inhibit JAK have been developed in recent years, and many are currently undergoing clinical trials. XELJANZ (tofacitinib) has been approved by the US Food and Drug Administration as the first small-molecule JAK pathway inhibitor for the treatment of moderately to severely active RA.

Biotechnology Advances

The market for anti-inflammatory medications is shifting towards biologic drugs, which are produced from live cells and have various advantages over traditional small-molecule drugs. Biologics are extremely targeted and target the root causes of inflammation, resulting in better efficacy and fewer adverse effects. Furthermore, biologics have longer patent lifetimes than standard pharmaceuticals, which can assist producers in maintaining profitability and market position. Biosimilars, which are similar but not identical to existing biologics, are also boosting market expansion by offering patients with more economical options. To capitalise on these prospects, pharmaceutical companies are investing in R&D to develop new biologics and biosimilars that potentially enhance patient outcomes while lowering prices.

In order to fulfil the increased demand for these treatments, they are also expanding their manufacturing capacities. Overall, biologics breakthroughs give a substantial opportunity for the anti-inflammatory medicine market to grow and evolve in the next years.

Competitive Landscape

Key Players

The global anti-inflammatory drugs market is highly competitive, with the presence of several key players. Some of the major players in the market and their market share are as follows:

• AbbVie Inc.
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Novartis AG
• GlaxoSmithKline plc.
• Eli Lilly and Company
• Amgen Inc.
• Biogen
• Others

These companies focus on product innovation, expanding their distribution channels, and mergers and acquisitions to stay ahead in the market.

The major players in the global anti-inflammatory drugs market are constantly striving to stay ahead by introducing new products and innovations.

Strides Pharma stated on August 2022, that the US Food and Drug Administration (USDA) had approved its Naproxen Sodium Softgel Capsules. Naproxen sodium softgel capsules are a nonsteroidal anti-inflammatory medication used to treat pain or inflammation caused by conditions such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps. It can also be used to relieve acute pain caused by other illnesses. The US OTC market for Naproxen Sodium Softgel Capsules is estimated to be worth USD 100 million.

HUMIRA (adalimumab), according to a February 2021 release from AbbVie, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderately to very active ulcerative colitis in individuals 5 years of age and older.

Pfizer Inc. reports that the FDA approved tofacitinib, the substance that makes up XELJANZ XR, for the once-daily treatment of adult patients with moderately to severely active arthritis in October 2020.

Summary of Key Findings

• The prevalence of inflammation-related illnesses and potential pipeline candidates is rising is driving market growth
• Market segmented by drug class, application, route of administration, distribution channel, and region.
• In 2022, the oral segment led the market with a market share of roughly 56%.
• With a market share of roughly 54% in 2022, the retail pharmacies segment dominated the industry.
• With a market share of roughly 39.88%, North America emerged as the largest market for worldwide anti-inflammatory drugs..

Future Outlook

• In the upcoming years, it is anticipated that the global market for anti-inflammatory medications would expand dramatically.
• The market is being pushed by factors such the rising prevalence of chronic diseases, the growing elderly population, and the rising cost of healthcare.
• The development of novel and cutting-edge anti-inflammatory medications, such as biologics and biosimilars, is also driving the market.
• Although the Asia-Pacific area is anticipated to experience the biggest growth in the coming years, North America is currently the region with the largest market for anti-inflammatory medications.
• Pfizer, Novartis, Merck, Johnson & Johnson, and GlaxoSmithKline are a few of the market’s major participants.

Segmentation

• By Drug Class
• Anti-inflammatory Biologics
• Non-steroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• By Application
• Autoimmune Inflammatory Diseases
• Respiratory Diseases
• Others
• By Route of Administration
• Oral
• Injection
• Topical
• Inhalation
• By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• By Region
• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa